Decreased muscarinic receptor binding in cerebral cortex and hippocampus in Alzheimer's disease
- PMID: 3600187
- DOI: 10.1016/0024-3205(87)90221-9
Decreased muscarinic receptor binding in cerebral cortex and hippocampus in Alzheimer's disease
Abstract
Muscarinic (cholinergic) receptor binding sites (MRB) were studied by determining the 3H-QNB binding in four cortical areas and hippocampus of 20 histologically confirmed Alzheimer patients and comparing these with corresponding controls. Alzheimer patients dying at younger age (less than or equal to 80) with profound decrease in choline-acetyltransferase activity (by 61-85%) and without any, possibly MRB modifying, drug treatment showed 30% decrease in MRB in the frontal cortex (p less than 0.05), 28% in the temporal cortex (p less than 0.05) and 37% in the hippocampus (p less than 0.01). These findings further suggest that muscarinic receptors are affected in Alzheimer's disease, at least in advanced state of the disease.
Similar articles
-
Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-type dementia.J Neurochem. 1986 Jan;46(1):288-93. doi: 10.1111/j.1471-4159.1986.tb12960.x. J Neurochem. 1986. PMID: 3940287
-
Muscarinic and nicotinic cholinergic binding sites in Alzheimer's disease cerebral cortex.Brain Res. 1987 Dec 8;436(1):62-8. doi: 10.1016/0006-8993(87)91556-3. Brain Res. 1987. PMID: 3690354
-
Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia.Brain Res. 1982 Jan 28;232(1):129-39. doi: 10.1016/0006-8993(82)90615-1. Brain Res. 1982. PMID: 7055689
-
Pre- and post-synaptic cholinergic dysfunction in aged rodent brain regions: new findings and an interpretative review.Int J Dev Neurosci. 1990;8(6):689-708. doi: 10.1016/0736-5748(90)90063-8. Int J Dev Neurosci. 1990. PMID: 2288244 Review.
-
Muscarinic receptor subtypes in human neurodegenerative disorders: focus on Alzheimer's disease.Trends Pharmacol Sci. 1989 Dec;Suppl:80-4. Trends Pharmacol Sci. 1989. PMID: 2694529 Review.
Cited by
-
Differential cholinergic regulation in Alzheimer's patients compared to controls following chronic blockade with scopolamine: a SPECT study.Psychopharmacology (Berl). 1995 Sep;121(2):231-41. doi: 10.1007/BF02245634. Psychopharmacology (Berl). 1995. PMID: 8545529
-
Combined Effects of Intermittent Hypoxia and Amyloid Beta on Hippocampal Activity, Its Cholinergic Modulation, and Memory.Hippocampus. 2025 Jul;35(4):e70017. doi: 10.1002/hipo.70017. Hippocampus. 2025. PMID: 40495777 Free PMC article.
-
Increased CSF HVA response to arecoline challenge in Alzheimer's disease.J Neural Transm Gen Sect. 1992;90(1):53-65. doi: 10.1007/BF01250518. J Neural Transm Gen Sect. 1992. PMID: 1281646
-
Novel Variance-Component TWAS method for studying complex human diseases with applications to Alzheimer's dementia.PLoS Genet. 2021 Apr 2;17(4):e1009482. doi: 10.1371/journal.pgen.1009482. eCollection 2021 Apr. PLoS Genet. 2021. PMID: 33798195 Free PMC article.
-
Muscarinic receptor occupancy and cognitive impairment: a PET study with [11C](+)3-MPB and scopolamine in conscious monkeys.Neuropsychopharmacology. 2011 Jun;36(7):1455-65. doi: 10.1038/npp.2011.31. Epub 2011 Mar 23. Neuropsychopharmacology. 2011. PMID: 21430646 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical